Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Immunity. 2018 Feb 20;48(2):243-257.e10. doi: 10.1016/j.immuni.2018.01.012.
T cell development is orchestrated by transcription factors that regulate the expression of genes initially buried within inaccessible chromatin, but the transcription factors that establish the regulatory landscape of the T cell lineage remain unknown. Profiling chromatin accessibility at eight stages of T cell development revealed the selective enrichment of TCF-1 at genomic regions that became accessible at the earliest stages of development. TCF-1 was further required for the accessibility of these regulatory elements and at the single-cell level, it dictated a coordinate opening of chromatin in T cells. TCF-1 expression in fibroblasts generated de novo chromatin accessibility even at chromatin regions with repressive marks, inducing the expression of T cell-restricted genes. These results indicate that a mechanism by which TCF-1 controls T cell fate is through its widespread ability to target silent chromatin and establish the epigenetic identity of T cells.
T 细胞的发育是由转录因子来调控的,这些转录因子可以调节最初被隐藏在不可接近的染色质中的基因的表达。然而,能够确定 T 细胞谱系调控景观的转录因子仍然未知。在 T 细胞发育的八个阶段对染色质可及性进行分析后发现,TCF-1 选择性地富集在基因组区域,这些区域在发育的最早阶段变得可及。TCF-1 进一步促进了这些调控元件的可及性,在单细胞水平上,它决定了 T 细胞中染色质的协调打开。成纤维细胞中 TCF-1 的表达甚至可以在具有抑制性标记的染色质区域产生新的染色质可及性,从而诱导 T 细胞受限基因的表达。这些结果表明,TCF-1 控制 T 细胞命运的机制是通过其广泛的靶向沉默染色质的能力,并建立 T 细胞的表观遗传特征。
Nat Rev Genet. 2019-4
Nat Immunol. 2019-7-29
Biochim Biophys Acta Gene Regul Mech. 2017-1-8
Nature. 2025-8-20
Front Immunol. 2025-7-17
Nat Immunol. 2025-5-21
Nat Immunol. 2025-4
Nat Rev Immunol. 2025-1-28
J Immunother Cancer. 2024-11-7